Key Highlights

• Merck's growth remains anchored by Keytruda, one of the world's best-selling cancer therapies, which continues to drive Revenue, Earnings, and Cash Flow growth.
• The pharmaceutical giant combines a strong oncology Franchise, leading Vaccine portfolio, and attractive Dividend, making it a significant S&P 500 healthcare holding.
• Investors are closely monitoring Merck's pipeline development and strategy to offset the anticipated Keytruda Patent cliff later this decade.

Merck & Co. Inc. (NYSE: MRK) is one of the largest pharmaceutical companies in the S&P 500, with a market Capitalization around $298 billion in mid-2026. A global leader in prescription medicines and vaccines, Merck is best known for Keytruda, one of the world's top-selling cancer immunotherapies, which anchors its Business.

For investors, Merck offers exposure to the pharmaceutical sector through a company with a dominant oncology franchise, a meaningful dividend and a deep pipeline. Its strengths in cancer treatment and vaccines, along with its research capabilities, make it a significant health-care holding, though it faces a major patent challenge later this decade.

Business overview: oncology, vaccines and more

Merck is a research-driven pharmaceutical company with a portfolio spanning oncology, vaccines, infectious diseases, cardiovascular and other areas, along with an animal-health business. Its defining product is Keytruda, an immunotherapy used to treat a wide range of cancers, which has become one of the best-selling medicines in the world.

Keytruda is central to Merck's business. In the first quarter of 2026, Keytruda sales topped $8.03 billion, up 12%, driven by increased use in earlier-stage cancers and strong Demand for metastatic indications. Merck has been expanding Keytruda's approved uses and developing new formulations to extend its franchise.

Beyond Keytruda, Merck markets important vaccines, including for HPV and other diseases, and other medicines, and is investing in its pipeline to develop new oncology, cardiovascular and other treatments. In the first quarter of 2026, total worldwide sales were $16.3 billion, up 5%, reflecting Keytruda's strength and contributions from newer products.

Recent share-price performance and market context

Merck shares have traded around $121 in mid-2026, reflecting solid results balanced against investor focus on the looming loss of exclusivity for Keytruda later this decade. The stock is valued for its current earnings and dividend, with the patent cliff a key consideration for its longer-term outlook.

The first quarter of 2026 was strong, with total sales of $16.3 billion, up 5%, led by Keytruda's outperformance. Merck narrowed its 2026 sales guidance to between $65.8 billion and $67 billion and raised its adjusted profit outlook to between $5.04 and $5.16 per share, reflecting confidence in its near-term trajectory.

The market context for Merck involves the strength of Keytruda, the pipeline's ability to offset its eventual patent loss, drug-pricing dynamics and the broader pharmaceutical environment. Investors weigh Merck's strong current franchise against the need to replace Keytruda's revenue over time.

Key growth drivers

Keytruda is the central growth driver. As one of the world's top-selling medicines, Keytruda continues to grow through expanded use in earlier-stage and additional cancers. Merck is also developing a subcutaneous formulation to help extend the franchise.

Vaccines and other products support growth. Merck's vaccine franchise, including for HPV, and other medicines provide additional revenue and growth, diversifying beyond oncology.

The pipeline is critical to the long-term outlook. Merck is investing heavily in developing new oncology, cardiovascular and other treatments, along with business-development deals, to build the next generation of products that can offset Keytruda's eventual patent loss.

Merck's research capabilities, scale and commercial strength support its ability to develop and launch new medicines, which is essential to its Long-term Growth.

Major risks investors should watch

The Keytruda patent cliff is the foremost risk. Merck relies heavily on Keytruda, which will eventually lose exclusivity and face biosimilar competition later this decade. Replacing this enormous revenue stream is the central long-term challenge for the company.

Pipeline and execution risk is significant. Merck must successfully develop or acquire new products to offset Keytruda's eventual decline. Pipeline setbacks or an inability to build new blockbusters would weigh on its long-term outlook.

Drug-pricing and regulatory pressures affect the sector. Policy changes, pricing negotiations and reimbursement decisions could pressure Merck's revenue, particularly for its largest products.

Finally, concentration in Keytruda heightens these risks, as the company's reliance on a single product makes it especially exposed to that franchise's trajectory and eventual patent loss.

Earnings, revenue, margins and Balance Sheet

Merck's financials reflect a strong current franchise. First-quarter 2026 total sales of $16.3 billion, up 5%, led by Keytruda topping $8 billion, with raised adjusted profit guidance, demonstrated solid performance and the strength of its oncology business.

Margins are healthy, supported by the profitability of Keytruda and Merck's other branded medicines. The company invests substantially in Research and Development to build its pipeline, which is essential to offsetting the eventual Keytruda patent loss.

Merck generates strong cash flow, which supports its dividend, research Investment, share repurchases and business-development deals. The company maintains a solid balance sheet, giving it the capacity to invest in its pipeline and pursue acquisitions to strengthen its long-term position.

The central financial dynamic is Merck's strong current earnings, driven by Keytruda, balanced against the need to invest heavily in its pipeline to replace that franchise's revenue before its patent expires.

Dividend discussion

Merck pays a solid and growing dividend, with an annual payout of about $3.40 per share and a Yield around 2.9%, attractive relative to the broad market. Merck has increased its dividend for 16 consecutive years, reflecting steady cash generation.

Merck's dividend is a meaningful part of its investment appeal, supported by its strong current earnings. The company also returns Capital through share repurchases and invests in its pipeline. For income investors, Merck's above-market yield and dividend growth are attractive, though sustainability over the long term depends on offsetting the Keytruda patent loss.

Valuation discussion

Merck is typically valued on price-to-earnings and dividend-yield metrics, with its valuation reflecting strong current earnings balanced against the looming Keytruda patent cliff. The stock's multiple incorporates concerns about its longer-term growth.

Bulls argue that Merck's strong current franchise, dividend and pipeline, along with its research capabilities, justify its valuation and that it can develop new products to offset Keytruda's eventual decline. Skeptics emphasize the patent cliff and the uncertainty of replacing such a large revenue stream.

The valuation case rests on Merck's ability to grow its pipeline and offset the Keytruda patent loss. Its valuation reflects the tension between strong current earnings and longer-term uncertainty.

Analyst-style outlook

Analysts hold a range of views on Merck, with some emphasizing its strong Keytruda franchise, dividend and pipeline, and others cautious about the eventual patent cliff. The bullish case rests on near-term strength and pipeline development.

The cautious case focuses on the Keytruda patent loss and the challenge of replacing its revenue, along with drug-pricing pressures. Observers will watch Keytruda sales, pipeline progress, business-development deals and the dividend.

Conclusion: what investors should watch next

Merck remains a leading pharmaceutical company in the S&P 500, anchored by its dominant Keytruda oncology franchise, a meaningful dividend and a deep pipeline. Its latest results showed strong sales led by Keytruda and a raised profit outlook.

The signals to monitor are Keytruda sales and lifecycle developments, pipeline progress and new product launches, business-development activity to bolster the pipeline, drug-pricing developments, and the dividend. The pipeline's ability to offset the eventual Keytruda patent loss will be especially important.

For investors, Merck offers a strong current franchise and an attractive dividend, balanced by the major challenge of replacing Keytruda's revenue before its patent expires. How its pipeline develops will determine its longer-term trajectory.